Microbiota in Cancer Development and Treatment

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2018 Dec 14

PMID 30542789

Citations 45

Authors

Muhammad Hassan Raza

Kamni Gul

Abida Arshad

Naveeda Riaz

Usman Waheed

Abdul Rauf

Fahad Aldakheel

Shatha Alduraywish

Maqbool Ur Rehman

Muhammad Abdullah

Muhammad Arshad

Affiliations

Soon will be listed here.

Abstract

Purpose: Human microbiota comprises of a variety of organisms ranging from bacterial species to viruses, fungi, and protozoa which are present on the epidermal and mucosal barriers of the body. It plays a key role in health and survival of the host by regulation of the systemic functions. Its apparent functions in modulation of the host immune system, inducing carcinogenesis and regulation of the response to the cancer therapy through a variety of mechanisms such as bacterial dysbiosis, production of genotoxins, pathobionts, and disruption of the host metabolism are increasingly becoming evident.

Methods: Different electronic databases such as PubMed, Google Scholar, and Web of Science were searched for relevant literature which has been reviewed in this article.

Results: Characterization of the microbiome particularly gut microbiota, understanding of the host-microbiota interactions, and its potential for therapeutic exploitation are necessary for the development of novel anticancer therapeutic strategies with better efficacy and lowered off-target side effects.

Conclusion: In this review, the role of microbiota is explained in carcinogenesis, mechanisms of microbiota-mediated carcinogenesis, and role of gut microbiota in modulation of cancer therapy.

Citing Articles

The Bidirectional Impact of Cancer Radiotherapy and Human Microbiome: Microbiome as Potential Anti-tumor Treatment Efficacy and Toxicity Modulator.

Palkovsky M, Modrackova N, Neuzil-Bunesova V, Liberko M, Soumarova R In Vivo. 2024; 39(1):37-54.

PMID: 39740900 PMC: 11705129. DOI: 10.21873/invivo.13803.

Cancer and the Microbiome of the Human Body.

Herrera-Quintana L, Vazquez-Lorente H, Lopez-Garzon M, Cortes-Martin A, Plaza-Diaz J Nutrients. 2024; 16(16).

PMID: 39203926 PMC: 11357655. DOI: 10.3390/nu16162790.

Natural products can be potential inhibitors of metalloproteinase II from to intervene colorectal cancer.

Arif B, Yasir S, Saeed M, Fatmi M Heliyon. 2024; 10(12):e32838.

PMID: 39005891 PMC: 11239599. DOI: 10.1016/j.heliyon.2024.e32838.

Influence of Gut Microbiota-Mediated Immune Regulation on Response to Chemotherapy.

Deng Y, Hou X, Wang H, Du H, Liu Y Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794174 PMC: 11123941. DOI: 10.3390/ph17050604.

Approach to the diagnosis and management of dysbiosis.

Alagiakrishnan K, Morgadinho J, Halverson T Front Nutr. 2024; 11:1330903.

PMID: 38706561 PMC: 11069313. DOI: 10.3389/fnut.2024.1330903.

References

Pradere J, Dapito D, Schwabe R . The Yin and Yang of Toll-like receptors in cancer. Oncogene. 2013; 33(27):3485-95. PMC: 4059777. DOI: 10.1038/onc.2013.302. View

Huycke M, Gaskins H . Commensal bacteria, redox stress, and colorectal cancer: mechanisms and models. Exp Biol Med (Maywood). 2004; 229(7):586-97. DOI: 10.1177/153537020422900702. View

Fukata M, Shang L, Santaolalla R, Sotolongo J, Pastorini C, Espana C . Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis. 2011; 17(7):1464-73. PMC: 3117047. DOI: 10.1002/ibd.21527. View

Ha Y, Park D . Effects of DCA on Cell Cycle Proteins in Colonocytes. J Korean Soc Coloproctol. 2010; 26(4):254-9. PMC: 2998009. DOI: 10.3393/jksc.2010.26.4.254. View

Hold G, Smith M, Grange C, Watt E, El-Omar E, Mukhopadhya I . Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?. World J Gastroenterol. 2014; 20(5):1192-210. PMC: 3921503. DOI: 10.3748/wjg.v20.i5.1192. View

Dutton R, Turnbaugh P . Taking a metagenomic view of human nutrition. Curr Opin Clin Nutr Metab Care. 2012; 15(5):448-54. DOI: 10.1097/MCO.0b013e3283561133. View

Clarke G, Stilling R, Kennedy P, Stanton C, Cryan J, Dinan T . Minireview: Gut microbiota: the neglected endocrine organ. Mol Endocrinol. 2014; 28(8):1221-38. PMC: 5414803. DOI: 10.1210/me.2014-1108. View

Windey K, De Preter V, Verbeke K . Relevance of protein fermentation to gut health. Mol Nutr Food Res. 2011; 56(1):184-96. DOI: 10.1002/mnfr.201100542. View

Jones R, Desai C, Darby T, Luo L, Wolfarth A, Scharer C . Lactobacilli Modulate Epithelial Cytoprotection through the Nrf2 Pathway. Cell Rep. 2015; 12(8):1217-25. PMC: 4640184. DOI: 10.1016/j.celrep.2015.07.042. View

10.

Routy B, Letendre C, Enot D, Chenard-Poirier M, Mehraj V, Seguin N . The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation. Oncoimmunology. 2017; 6(1):e1258506. PMC: 5283637. DOI: 10.1080/2162402X.2016.1258506. View

11.

Bayerdorffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S . Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet. 1995; 345(8965):1591-4. DOI: 10.1016/s0140-6736(95)90113-2. View

12.

Vijay-Kumar M, Aitken J, Carvalho F, Cullender T, Mwangi S, Srinivasan S . Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010; 328(5975):228-31. PMC: 4714868. DOI: 10.1126/science.1179721. View

13.

Shen S, Wong C . Bugging inflammation: role of the gut microbiota. Clin Transl Immunology. 2016; 5(4):e72. PMC: 4855262. DOI: 10.1038/cti.2016.12. View

14.

Nyangale E, Mottram D, Gibson G . Gut microbial activity, implications for health and disease: the potential role of metabolite analysis. J Proteome Res. 2012; 11(12):5573-85. DOI: 10.1021/pr300637d. View

15.

Mittal D, Saccheri F, Venereau E, Pusterla T, Bianchi M, Rescigno M . TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J. 2010; 29(13):2242-52. PMC: 2905255. DOI: 10.1038/emboj.2010.94. View

16.

Ochi A, Nguyen A, Bedrosian A, Mushlin H, Zarbakhsh S, Barilla R . MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J Exp Med. 2012; 209(9):1671-87. PMC: 3428946. DOI: 10.1084/jem.20111706. View

17.

Petnicki-Ocwieja T, Hrncir T, Liu Y, Biswas A, Hudcovic T, Tlaskalova-Hogenova H . Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci U S A. 2009; 106(37):15813-8. PMC: 2747201. DOI: 10.1073/pnas.0907722106. View

18.

Boleij A, Hechenbleikner E, Goodwin A, Badani R, Stein E, Lazarev M . The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis. 2014; 60(2):208-15. PMC: 4351371. DOI: 10.1093/cid/ciu787. View

19.

Dong L, Li J, Liu Y, Yue W, Luo X . Toll-like receptor 2 monoclonal antibody or/and Toll-like receptor 4 monoclonal antibody increase counts of Lactobacilli and Bifidobacteria in dextran sulfate sodium-induced colitis in mice. J Gastroenterol Hepatol. 2011; 27(1):110-9. DOI: 10.1111/j.1440-1746.2011.06839.x. View

20.

Faith J, Guruge J, Charbonneau M, Subramanian S, Seedorf H, Goodman A . The long-term stability of the human gut microbiota. Science. 2013; 341(6141):1237439. PMC: 3791589. DOI: 10.1126/science.1237439. View